Hospital

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.

Results demonstrated a 64.5% confirmed objective response rate in patients treated with the investigational combination.

Ribociclib with endocrine therapy was found to increase the median overall survival of patients with HR+/HER2- advanced breast cancer with visceral metastases to nearly 5 years.

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

Case report describes severe complications from spontaneous bladder rupture caused by herpes zoster-associated urinary retention.

Asceniv is a plasma-derived polyclonal IVIG drug product designed to prevent serious bacterial infections in patients with primary humoral immunodeficiency disease.

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.

Pharmacy Times spoke with Carina Dolan, PharmD, Editor in Chief of the Pharmacy Market Outlook, about the highlights and the big picture moving forward for hospitals and health systems.

Data presented at the European Society for Medical Oncology Congress showed that sotorasib increased progression-free survival to 1 year in 25% of patients with KRAS G12C-mutated non-small cell lung cancer.

Researchers expect to file for FDA approval within the year following the successful phase 3 trial.

Receiving 3 doses of the COVID-19 vaccine can offer better and more long-lasting protection against the Omicron variant.

Fruquintinib reduced the risk of death in patients with advanced metastatic colorectal cancer by 34% and led to longer overall survival than among those given placebo.

Sunvozertinib is an oral, potent EGFR exon20ins inhibitor with wild-type EGFR selectivity.

But the 2021 modifications to the US Preventive Services Task Force recommendations do not eliminate the inequalities, analysis shows.

The findings also indicate that that treatment may have protective CV and limb benefits for those with kidney failure and concomitant peripheral artery disease.

Viral antigen levels in blood plasma can provide clinically important patient outcomes among hospitalized patients with COVID-19.

Prescription drug monitoring programs have decreased prescription opioids in the United States but resulted in unintended spikes of illegal drug use and heroin-related deaths.

The percentage of infections, hospitalizations, and deaths that were prevented from COVID-19 vaccination increased with greater vaccine coverage, according to a recent study.

Study suggests that myeloma patient survival after BCMA-targeted T-cell therapy could be determined by microenvironment factors.

Nintedanib is a tyrosine kinase inhibitor targeting key receptors involved in signaling pathways that led to pulmonary fibrosis.

Children younger than age 6 years might be protected from other COVID-19 variants for up to a year after infection.

Obesity, heavy alcohol consumption, and coagulopathy were some of the greatest risk factors associated with patients returning to the operating room within 48 hours of a surgery.

Pharmacists handle public vaccination efforts and need to assess where patients are on the hesitancy spectrum to provide reliable information.

New TROPiCS-02 data for Gilead treatment demonstrates progression-free survival benefit, regardless of HER2 status.

Patients should discuss efficacy and potential drug interactions with clinicians before use, study authors indicate.

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

Dolutegravir is a more recently approved ART that is a part of a once-a-day regimen found to be more effective, easier to tolerate, and less likely to create new drug resistance in people with HIV-1 compared with other antiretroviral drugs.

Sacrosidase was approved by the FDA to treat congenital sucrase-isomaltase deficiency, a condition that inhibits people from breaking down sucrose.